DGIdb - CILENGITIDE Drug Record

CILENGITIDE chembl:CHEMBL429876 Antineoplastic

Alternate Names:

EMD-12192
EMD-121974
EMD 121974
CILENGITIDE

Drug Info:

FDA Approval	not approved
Drug Class	peptide
Drug Indications	antineoplastic agent

(4 More Sources)

Publications:

Monaco A et al., 2013, Synthesis and in vitro evaluation of a novel radioligand for αvβ3 integrin receptor imaging: [18F]FPPA-c(RGDfK)., Bioorg Med Chem Lett
Burke et al., 2002, Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts., Cancer Res.

CILENGITIDE ITGB5

Interaction Score: 9.27

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes Targets ALPHA-V/BETA-3 INTEGRIN

Trial Name cilengitide. EMD-121974

Novel drug target Novel Target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial ChemblInteractions
CILENGITIDE ITGAV

Interaction Score: 6.18

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Integrin alpha-V/beta-3 antagonist

Notes Targets ALPHA-V/BETA-5 INTEGRIN

PMIDs:
24095096

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions
CILENGITIDE ITGB3

Interaction Score: 4.42

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name cilengitide. EMD-121974

Novel drug target Established target

Mechanism of Interaction Integrin alpha-V/beta-3 antagonist

PMIDs:
24095096

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions
CILENGITIDE ITGA5

Interaction Score: 1.77

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name cilengitide. EMD-121974

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
CILENGITIDE BCL2

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12154028

Sources:
NCI

TdgClinicalTrial: CILENGITIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class peptide

FDA Approval not approved

Publications:
NCI: CILENGITIDE
- Version: 14-September-2017
Alternate Names:

C1834 NCI drug code

Drug Info:

Publications:

Burke et al., 2002, Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts., Cancer Res.
DTC: CILENGITIDE
- Version: 02-September-2020
Alternate Names:

CHEMBL429876 ChEMBL Drug ID

Drug Info:

Publications:

Monaco A et al., 2013, Synthesis and in vitro evaluation of a novel radioligand for αvβ3 integrin receptor imaging: [18F]FPPA-c(RGDfK)., Bioorg Med Chem Lett
TALC: CILENGITIDE
- Version: 12-May-2016
Alternate Names:

CILENGITIDE Primary Drug Name

CILENGITIDE Drug Generic Name

EMD121974 Drug Synonym

Drug Info:

Publications:
TTD: Cilengitide
- Version: 2020.06.01
Alternate Names:

D09ZXO TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL429876
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: CILENGITIDE
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL429876
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Notes	Targets ALPHA-V/BETA-3 INTEGRIN
Trial Name	cilengitide. EMD-121974
Novel drug target	Novel Target

Direct Interaction	yes
Mechanism of Interaction	Integrin alpha-V/beta-3 antagonist
Notes	Targets ALPHA-V/BETA-5 INTEGRIN

CILENGITIDE	Primary Drug Name
CILENGITIDE	Drug Generic Name
EMD121974	Drug Synonym

antagonist (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

CILENGITIDE Drug Record

CILENGITIDE chembl:CHEMBL429876 Antineoplastic

Alternate Names:

Drug Info:

Publications:

CILENGITIDE ITGB5

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Notes Targets ALPHA-V/BETA-3 INTEGRIN Trial Name cilengitide. EMD-121974 Novel drug target Novel Target

PMIDs: None found

Sources: TALC TdgClinicalTrial ChemblInteractions

CILENGITIDE ITGAV

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Integrin alpha-V/beta-3 antagonist Notes Targets ALPHA-V/BETA-5 INTEGRIN

PMIDs: 24095096

Sources: TALC DTC TdgClinicalTrial ChemblInteractions

CILENGITIDE ITGB3

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name cilengitide. EMD-121974 Novel drug target Established target Mechanism of Interaction Integrin alpha-V/beta-3 antagonist

PMIDs: 24095096

Sources: TALC DTC TdgClinicalTrial ChemblInteractions

CILENGITIDE ITGA5

Interaction Types & Directionality: n/a

Interaction Info: Trial Name cilengitide. EMD-121974 Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial

CILENGITIDE BCL2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12154028

Sources: NCI

TdgClinicalTrial: CILENGITIDE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class peptide FDA Approval not approved

Publications:

NCI: CILENGITIDE

Alternate Names: C1834 NCI drug code

Drug Info:

Publications: Burke et al., 2002, Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts., Cancer Res.

DTC: CILENGITIDE

Alternate Names: CHEMBL429876 ChEMBL Drug ID

Drug Info:

Publications: Monaco A et al., 2013, Synthesis and in vitro evaluation of a novel radioligand for αvβ3 integrin receptor imaging: [18F]FPPA-c(RGDfK)., Bioorg Med Chem Lett

TALC: CILENGITIDE

Alternate Names: CILENGITIDE Primary Drug Name CILENGITIDE Drug Generic Name EMD121974 Drug Synonym

Drug Info:

Publications:

TTD: Cilengitide

Alternate Names: D09ZXO TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL429876

Alternate Names:

Drug Info:

Publications:

MyCancerGenomeClinicalTrial: CILENGITIDE

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL429876

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes Targets ALPHA-V/BETA-3 INTEGRIN

Trial Name cilengitide. EMD-121974

Novel drug target Novel Target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Integrin alpha-V/beta-3 antagonist

Notes Targets ALPHA-V/BETA-5 INTEGRIN

PMIDs:
24095096

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name cilengitide. EMD-121974

Novel drug target Established target

Mechanism of Interaction Integrin alpha-V/beta-3 antagonist

PMIDs:
24095096

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name cilengitide. EMD-121974

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
12154028

Sources:
NCI

Drug Info:

Drug Indications antineoplastic agent

Drug Class peptide

FDA Approval not approved

Alternate Names:

C1834 NCI drug code

Publications:

Burke et al., 2002, Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts., Cancer Res.

Alternate Names:

CHEMBL429876 ChEMBL Drug ID

Publications:

Monaco A et al., 2013, Synthesis and in vitro evaluation of a novel radioligand for αvβ3 integrin receptor imaging: [18F]FPPA-c(RGDfK)., Bioorg Med Chem Lett

Alternate Names:

CILENGITIDE Primary Drug Name

CILENGITIDE Drug Generic Name

EMD121974 Drug Synonym

Alternate Names:

D09ZXO TTD Drug ID